Youli Pan
Sichuan University(CN)Science and Technology Department of Sichuan Province(CN)State Key Laboratory of Biotherapy
Publications by Year
Research Areas
Cancer, Hypoxia, and Metabolism, Angiogenesis and VEGF in Cancer, Colorectal Cancer Treatments and Studies, Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research
Most-Cited Works
- → SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth In Vivo(2011)101 cited
- → Discovery of Novel Pim-1 Kinase Inhibitors by a Hierarchical Multistage Virtual Screening Approach Based on SVM Model, Pharmacophore, and Molecular Docking(2011)72 cited
- → YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models(2014)33 cited
- → A Preclinical Evaluation of SKLB261, a Multikinase Inhibitor of EGFR/Src/VEGFR2, as a Therapeutic Agent against Pancreatic Cancer(2014)30 cited
- → Combined SVM-based and docking-based virtual screening for retrieving novel inhibitors of c-Met(2011)26 cited
- → SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo(2012)22 cited
- → Systems Biology Modeling Reveals a Possible Mechanism of the Tumor Cell Death upon Oncogene Inactivation in EGFR Addicted Cancers(2011)11 cited
- → Identification of Novel Anaplastic Lymphoma Kinase (ALK) Inhibitors Using a Common Feature Pharmacophore Model Derived from Known Ligands Crystallized with ALK(2012)4 cited
- → Data from SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i>(2023)
- → Data from A Preclinical Evaluation of SKLB261, a Multikinase Inhibitor of EGFR/Src/VEGFR2, as a Therapeutic Agent against Pancreatic Cancer(2023)